Sleep continuity
Older trials investigated whether DSIP could normalise disturbed sleep.
Explore the research →SLEEP & NEUROENDOCRINE RESEARCH
DSIP
An experimental peptide most often associated with sleep, relaxation and the body's response to stress. Human findings are limited and mixed.
Insomnia researchSleep architectureStress biology
Small, old and inconsistent human studiesDSIP has direct human sleep research, including a double-blind insomnia study, but results are modest, the mechanism remains unresolved and modern replication is lacking.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
What is the real evidence behind DSIP?
DSIP has remained interesting because sleep sits at the centre of its story. Research has explored whether it can influence falling asleep, sleep quality, stress and the body's overnight rhythms — all areas that matter to people looking for better rest and recovery.
Stress-response biology
DSIP has also been studied beyond sleep in neuroendocrine and stress models.
Explore the research →Daytime recovery
Users hope that better sleep will improve daytime energy and wellbeing.
Explore the research →THE SCIENCE BIT
Sleep biology without a confirmed master switch.
DSIP stands for delta sleep-inducing peptide, a name drawn from early experiments. Researchers have explored sleep patterns, stress responses and neuroendocrine effects.
A specific, well-established DSIP receptor has not been identified. It is best understood as a sleep-related research hypothesis, with small and inconsistent human studies rather than a predictable on–off sleep mechanism.
See the studies & trials →- Sleep networks
- The research focus
- Stress responses
- An experimental theme
- Target uncertain
- No established specific receptor
How this connects to the research
Mechanism and human efficacy remain uncertain.
FROM MOLECULE TO TISSUE
Where DSIP connects with the body
These are the tissues and biological systems behind the interest in DSIP.
- Brain
- Sleep and wakefulness studies.
- Neuroendocrine systems
- Hormone-related hypotheses.
- Circadian context
- Timing and sleep architecture.
The research behind the interest
Sleep continuity
Older trials investigated whether DSIP could normalise disturbed sleep.
Small studies reported some delayed or night-specific effects rather than a clear, immediate sedative action.
Limited human evidenceExplore the studies →Sleep architecture
Researchers measured EEG stages and 24-hour sleep patterns.
Results varied across timing, population and protocol, with no robust modern efficacy programme.
Mixed human evidenceExplore the studies →Stress-response biology
DSIP has also been studied beyond sleep in neuroendocrine and stress models.
Most stress-protection findings are experimental and do not establish a clinical benefit.
Preclinical evidenceExplore the studies →Daytime recovery
Users hope that better sleep will improve daytime energy and wellbeing.
No strong trial evidence shows durable improvements in daytime function from DSIP treatment.
Unproven clinical benefitExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableEffects of DSIP on sleep of chronic insomniac patients ↗
16 people with chronic insomnia
Intravenous · 25 nmol/kgAfternoons before nights 3, 4 and 55-night laboratory protocol
Sleep efficiency was higher and sleep latency shorter in the DSIP group during parts of the protocol.
The authors described the effects as weak and noted that some differences may have reflected incidental placebo-group changes.
Effects of DSIP on 24-hour sleep and wakefulness ↗
Human volunteers in intermediate-term administration research
Sleep-wake effects were assessed over 24 hours.
The wider literature remained inconsistent enough for later reviews to describe DSIP as unresolved.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
Several small human sleep studies exist, mainly from the 1980s and early 1990s.
✓
Clinical efficacyEarly
1/5 evidence depth
Results are inconsistent and have not established DSIP as an insomnia treatment.
◇
Safety evidenceEarly
1/5 evidence depth
Short studies provide limited tolerability information; long-term safety is undefined.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Animal and neuroendocrine studies support multiple possible actions but no settled receptor mechanism.
HOW TO READ THESE SCORESDeveloping preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEDSIPMechanism → measured response → clinical outcome
Small 1980s–1990s studies with variable findings
Multiple neuroendocrine ideas; no settled receptor story
Route, dose-response, daytime outcomes and long-term safety
Keep route, study setting and outcome together
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with DSIP
DSIP attracts people who want deeper sleep, fewer awakenings and better recovery. Its name and anecdotes are more convincing than the small, inconsistent clinical record.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Falling asleep with less struggle
People are interested in reducing the time spent awake at bedtime. The name creates a strong sleep-related expectation, while a meaningful experience needs to specify what actually changed.
- What makes a report informative
- Sleep onset under a similar bedtime routine.
- What can muddy the picture
- Expectancy, evening stress and schedule changes can alter sleep onset.
Staying asleep and waking restored
Interest includes fewer awakenings, a deeper-feeling night and less morning fatigue. These are separate outcomes; vivid dreams or a sedated feeling do not necessarily mean restorative sleep.
- What makes a report informative
- Night awakenings and next-day function.
- What can muddy the picture
- Consumer sleep-stage estimates are imperfect and do not establish deep-sleep improvement.
Recovery after stress or poor sleep
Some people hope that better sleep will improve recovery and daytime resilience. The useful question is whether sleep and function improve together, rather than treating a general reset feeling as proof.
- What makes a report informative
- Daytime energy alongside a consistent sleep record.
- What can muddy the picture
- Rest, reduced stress and other bedtime products can account for improvement.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Deeper or more restorative sleep
Users often describe vivid changes in perceived sleep depth.
Human findings & limits
Small sleep-lab studies reported variable and sometimes delayed effects.
Laboratory & animal context
EEG and neuroendocrine models suggest sleep-related activity, but mechanism is unresolved.
What this means: Direct human research exists, but does not establish reliable efficacy.
Faster sleep onset
The name suggests a direct sleep-inducing effect.
Human findings & limits
Historic studies did not consistently behave like a conventional immediate hypnotic.
Laboratory & animal context
Animal results vary by species, route and timing.
What this means: The label 'sleep-inducing' overstates the consistency of the evidence.
Stress and recovery
Some users discuss calmer nights and better physical recovery.
Human findings & limits
Robust daytime-function or stress-outcome trials are lacking.
Laboratory & animal context
Stress-response and mitochondrial findings have been reported in animal studies.
What this means: An experimental extension beyond the already uncertain sleep evidence.
Bedtime timing and short courses
Modern anecdotes usually describe use near bedtime, despite historic trials dosing in the afternoon.
Human findings & limits
The 1992 insomnia study used monitored IV dosing before three laboratory nights, not a retail nasal or subcutaneous course.
Laboratory & animal context
Route and timing can alter exposure and cannot be inferred from animal sleep models.
What this means: The community pattern is recognisable but not clinically validated.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA short bedtime pattern unlike the historic IV studies
This is a recurring modern community description. The published insomnia study used 25 nmol/kg intravenously in the afternoon under laboratory monitoring.
1Nights 1–3
100 mcg near bedtimeAnecdotal starting amount
2Nights 4–7
100–200 mcgOptional community-described step-up
3Nights 8–14
Up to 300 mcgUpper end of recurring descriptions
4After trial
Stop & reviewNo validated maintenance interval
What people commonly discuss100–300 mcg near bedtime for about 10–14 nights, with intermittent rather than continuous use also described.
What remains unvalidatedNo modern dose-finding trial validates these amounts, bedtime timing, nasal/subcutaneous equivalence or a cycling schedule.
ROUTE & DELIVERYHistoric intravenous exposure is not a modern route conversion
The small 1992 study administered 25 nmol/kg IV before three laboratory nights. Nasal and subcutaneous absorption have not been mapped against that protocol.
PROFESSIONAL SOURCE CONTEXT
1992 double-blind insomnia study ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Historic intravenous research protocols do not establish a modern intranasal or injected DSIP treatment schedule.
PUBLISHED HUMAN RESEARCH
View source ↗1992 chronic-insomnia laboratory study ↗
16 people with chronic insomnia
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved 16 people with chronic insomnia. Route: Given into a vein (IV). The study lasted 3 administrations within a 5-night protocol. The figures below describe the research design, not a personal schedule.
| First amount studied | 25 nmol/kg |
|---|---|
| How often? | Once each afternoon before 3 study nights |
| How was it given? | Given into a vein (IV) |
| How long? | 3 administrations within a 5-night protocol |
See the exact study wording +
Start / initial: 25 nmol/kg
End / target: 25 nmol/kg
Frequency: Once each afternoon before 3 study nights
Route: Intravenous
Study duration: 3 administrations within a 5-night protocol
Source: Bes et al., 1992 ↗
A small historic research protocol; not a validated clinical or community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · historic IV evidence differsWhat people commonly discuss
STARTING APPROACHES
Community descriptions often begin around 100 mcg near bedtime; 200–300 mcg is also discussed. This is not derived from a validated modern human protocol.
DURATION / CYCLES
A brief 10–14-night trial window is commonly described, sometimes with intermittent use rather than nightly continuation.
MAINTENANCE DISCUSSION
No validated step-up, continuous-use, tolerance-management or break schedule exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Eight-week editorial example
Community example · not clinically validatedSmall human sleep studies used intravenous, weight-based dosing and did not establish a routine insomnia treatment. They do not validate this subcutaneous escalation.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–1 | 100 mcg |
| Weeks 2–2 | 150 mcg |
| Weeks 3–3 | 200 mcg |
| Weeks 4–8 | 250 mcg |
Frequency: Every day · 1 entry per scheduled day.
The table shows 250 mcg final stage. Review the alternative described amounts in the planner before choosing an editable copy.
This is a finite editorial example. Its ending does not establish a safe course, break or repeat cycle. No repeat is added automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with DSIP
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDDSIP
→
OFTEN EXPLORED WITHDSIP + Epitalon
DSIP + Epitalon
→
OFTEN EXPLORED WITHDSIP + sleep routine
DSIP + Behavioural sleep programme
→
OFTEN EXPLORED WITHDSIP + Selank
DSIP + Selank
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
DDSIP IS USUALLY DISCUSSED AROUNDSleep continuity, architecture and neuroendocrine uncertainty
＋Historic human studies are small and inconsistent; modern bedtime use lacks a validated route or schedule.
PTHE PAIRED APPROACH MAY ADDCircadian peptide narratives or evidence-based sleep treatment
Epitalon is discussed around circadian biology, while CBT-I and sleep-disorder care have separate established roles.
＋
OFTEN EXPLORED WITH
Explore →＋DSIP + Epitalon
DSIP + EpitalonWHY IT IS EXPLOREDExplored around sleep, circadian rhythm and recovery.
No controlled human evidence for the combination.OFTEN EXPLORED WITH
Explore →＋DSIP + sleep routine
DSIP + Behavioural sleep programmeWHY IT IS EXPLOREDCommunities often combine peptide use with sleep-hygiene changes.
Behavioural changes confound anecdotes; CBT-I has a separate established evidence base.OFTEN EXPLORED WITH
Explore →DSIP + Selank
DSIP + SelankWHY IT IS EXPLOREDDiscussed around calmer nights, stress reduction and sleep continuity.
No controlled trial establishes efficacy, sedation risk or an appropriate combined schedule.01Identify the sleep problem
Insomnia, sleep apnoea, circadian delay and medication effects require different assessment.
02Protect breathing and alertness
Sedating combinations can worsen impairment or obscure an untreated sleep disorder.
03Track objective function
Daytime alertness and functioning matter more than a single night of perceived depth.
Safety context
SAFETY & UNCERTAINTY
Modern use is poorly matched to historic research
01ENCOURAGING CONTEXTHuman sleep-laboratory studies exist
DSIP is not supported only by animal work; objective sleep measures were collected in small monitored cohorts.
02THE IMPORTANT BOUNDARYThe name overstates the reliability
Findings were weak or inconsistent and did not establish a dependable sedative or insomnia treatment.
03WHAT REMAINS UNKNOWNModern-route and long-term safety
Nasal and subcutaneous exposure, endocrine effects, interactions and repeated-course safety are poorly characterised.
What the current evidence saysOlder intravenous studies cannot establish the safety of current intranasal or subcutaneous products. Long-term endocrine, neurological, interaction and product-quality risks are not adequately characterised.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sleep apnoea, restless legs, circadian disorders, depression and medication effects can all present as poor sleep.
Alcohol, hypnotics, opioids and other sedating agents can increase impairment even when DSIP interaction data are absent.
Driving impairment, confusion, unusual mood change or excessive daytime sleepiness requires review.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
7 sourcesSources used on this profile
Original publicationEffects of DSIP on sleep of chronic insomniac patientsJournal / DOI ↗Bibliographic recordEffects of DSIP on sleep of chronic insomniac patientsPubMed ↗Original publicationEffects of DSIP on 24-hour sleep and wakefulnessJournal / DOI ↗Bibliographic recordEffects of DSIP on 24-hour sleep and wakefulnessPubMed ↗Evidence reviewSafety and uncertaintyDSIP unresolved-riddle review ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
DSIP is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.